Immunoreactive ACTH (ir-ACTH) and immunoreactive b-endorphin (ir-bEP) were determined in plasma, anterior pituitary, neuro-intermediate lobe, and hypothalamus of sham-adrenalectomized rats, and adrenalectomized rats given six daily injections of vehicle (oil), dexamethasone, 9a-fluorocortisol or deoxycorticosterone. 6 d after adrenalectomy, anterior pituitary ir-ACTH and ir-bEP were double, and plasma levels approximately fivefold those in controls. Adrenalectomy did not alter hypothalamic levels of either peptide, or irbEP in neuro-intermediate lobe, in which tissue ir-ACTH was below detection limit at routine dilutions. Dexamethasone (0.2-200 µg/d) concurrently suppressed plasma ir-ACTH and ir-bEP, with a near maximal effect at 20 µg, and a half-maximal effect between 2 and 6 µg; similar dose-response characteristics were found for thymolysis.
similar dose-response characteristics were found for thymolysis.
Step-wise increases in anterior pituitary content of both peptides were found, with no change in hypothalamic levels of either peptide, or neuro-intermediate lobe ir-f3EP. 9a-fluorocortisol (0.2-200 ig/ d) produced plasma, anterior pituitary, and hypothalamic effects equivalent to dexamethasone, but with one-tenth the potency. Unlike dexamethasone, higher doses of 9a-fluorocortisol significantly elevated neurointermediate lobe ir-,BEP. Deoxycorticosterone (2-2,000 sg/d) produced no significant changes in plasma, anterior pituitary or hypothalamic levels of either peptide; like 9a-fluorocortisol, doses of >60 ug/d significantly elevated neuro-intermediate lobe ir-f3EP.
Whereas ir-ACTH and ir-,BEP synthesis in and release from the anterior pituitary are under complex negative feedback glucocorticoid control, there exists a mineralocorticoid-specific effect on neuro-intermediate lobe content of ir-f3EP. INTRODUCTION Pituitary secretion of adrenocorticotropic hormone (ACTH) is influenced both by hypothalamic corticotropin-releasing factor (CRF)' and circulating glucocorticoids. In the rat, feedback inhibition of corticosteroids on ACTH release acts at both the hypothalamic and pituitary level (1) . Under physiological conditions, hypothalamic CRF release is highly sensitive to inhibition by corticosterone, and thus CRF has been postulated as the major determinant of ACTH release (1) . Administration of glucocorticoids to intact animals lowers plasma ACTH to varying degrees, depending on steroid potency, dose, and period of treatment (2, 3) . Adrenalectomy removes the corticosteroid feedback inhibition, and increases both basal and CRFstimulated secretion (1, 4) . As a consequence, plasma levels and pituitary content of ACTH are concurrently elevated, the extent of change being related to the length of time postadrenalectomy (5, 6) .
Cell-free messenger RNA translation and pulsechase chromatographic studies have shown that a-endorphin (,BEP) and ACTH share a common, 31K dalton precursor in the anterior pituitary (7), neuro-intermediate lobe (8) , and hypothalamus (9) , although the posttranslational processing of the 31K precursor varies between tissues (10, 11) . There are some reports that plasma and pituitary immunoreactive (ir)-#EP, like ACTH, may be subject to glucocorticoid feedback inhibition; the area, however, remains one of some controversy. Adrenalectomy has been reported to re- ' Abbreviations used in this paper: aMSH, a-melanocytestimulating hormone; AP, anterior pituitary; ,-EP, fl-endorphin; CLIP, hACTH 18-39; CRF, corticotropin-releasing factor; CV, coefficient of variation; DM, dexamethasone; DOC, 11-deoxycorticosterone; HT, hypothalami; ir-flEP, immunoreactive ,3EP; N-IL, neuro-intermediate lobe; 9afF, 9a-fluorocortisol; PBS, phosphate-buffered saline; RIA, radioimmunoassay.
duce pituitary immunoreactive f3-endorphin (ir-#EP) (12) ; in contrast, long-term glucocorticoid treatment has also been reported (13) Radioimniunoassay of fIEP and ACTH. Heterologous double antibody RIA systems were used for the estimation of both ir-J3EP and ir-ACTH in tissue extracts and plasma. In the ,3EP RIA, synthetic human (3EP was used both for standards and for radioiodination. Anti-(3EP serum (R56) was raised in a rabbit immunized with ovine ,3EP conjugated to bovine serum albumin by I-ethyl-3(3-dimethylaminopropyl) carbodiimide, HCI. The resulting protein-antigen conjugates were dialyzed, lyophilized, and subsequently emulsified with Freund's complete adjuvant. The emulsion was injected at 2-4-wk intervals into rabbits at multiple intradermal sites until a satisfactory antibody titer was obtained. Donkey antirabbit gamma globulin (RD17) was used as second antibody in the RIA system. '25I-hj3EP tracer was prepared by iodinating 1-3 Mg hIEP with 1 mCi NaIl25 in the presence of 10 MAg chloramine-T for 30 s; the process was terminated by adding 10 lI of sodium metabisulphite, 3 mg/ml, in 0.01 M phosphate-buffered saline (PBS), 0.1% sodium azide, pH 7.5. The iodination mixture was loaded on a 1 X 15-cm Sephadex G-25 preequilibrated with PBS and coated with 2 ml of 2% bovine serum albumin. The iodination products were then eluted with 0.1% gelatin in PBS, and 20 X 0.8-ml fractions collected. Specific activity of the tracer ranged between 150-300 uCi/,gg; binding characteristics remained satisfactory for up to 5 wk of storage at -20°C.
The specific binding of 125I-fSEP to antiserum at a final dilution of 1:58,000 was 30%. Sensitivity, defined as the antigen concentration corresponding with the lower confidence limit of the number of counts specifically bound in the absence of unlabeled hormone, was 5±2.5 pg/tube (mean±SD, n = 7), representing 50 pg/ml assay sample. Nonspecific binding was routinely between 2 and 4.5%. The within assay coefficient of variation (CV), representing the variation of duplicates from the mean in six assays, was 8% at 125 pg/ tube, and was <10% over the range of 20 to 200 pg/tube (n = 6). The between assay CV was 15% at 20 and 200 pg/ tube (n = 14). 
RESULTS
Adrenalectomy and steroid administration. Effects on body weight and organ weights. The effect of adrenalectomy and steroid administration upon body weight and organ weights is shown in Fig. 1 ,ug/rat/doy FIGURE 1 Effect of DM (a), 9afF (A) Levels of ir-ACTH and ir-3EP. Effects of adrenalectomy. The effect of 6 d adrenalectomy on plasma and tissue levels of ir-ACTH and ir-,BEP is shown in Fig. 2 . Plasma levels of both peptides rose approximately fivefold above those found in sham adrenalectomized controls. Plasma ir-f3EP levels in sham adrenalectomized animals ranged from 220 to 357 pg/ml (284±32, mean±SEM), levels similar to those previously found by others in unstressed rats killed at the same time of day as those in the present study (21) .
Similarly, AP levels of both peptides rose after 6 d adrenalectomy to approximately double those in control, sham-adrenalectomized rats. In the hypothalamus, in contrast, no significant changes in ir-ACTH nor ir-f3EP were seen; adrenalectomy similarly did not appear to alter neuro-intermediate lobe levels of irf,EP. N-IL levels of ir-ACTH were universally below the sensitivity of the assay at the dilutions of tissue used.
Levels of ir-ACTH and ir-f3EP. Effects of DM. In adrenalectomized animals, increasing daily doses of dexamethasone produced progressive reductions in plasma levels of ir-ACTH and ir-,3EP, and a progressive elevation in anterior pituitary content of the two peptides (Fig. 3, upper panels) . No differences between doses were seen in the hypothalamus or neurointermediate lobe (Fig. 3, lower panels) There are, however, two differences between the dose-response curves for plasma and AP. First, the dose-response curve for AP ir-ACTH and ir-f3EP appears to have a different shape to that for suppression of plasma levels of the two peptides; whereas the latter appear to be classic sigmoid dose-response curves, those for AP content show equivalent increments over a three-orders-of-magnitude dose range. Secondly, whereas increasing doses of DM progressively suppress plasma levels, they progressively elevate AP content of both peptides. This is in sharp contrast with previous reports of no change (22) or a reduction (13, 23) in AP content of ir-ACTH/ir-I3EP after glucocorticoid administration. Such a finding presents an apparent paradox of an elevation in AP ir-ACTH and ir-f3EP following adrenal steroid withdrawal, with a further increase after steroid replacement. Possible reasons for this discrepancy between our studies and those of other authors (13, 22, 23) , and possible mechanisms of resolving the paradox, are discussed below.
Levels of ir-ACTH and ir-f3EP. Effects of 9afF.
9afF is a potent synthetic mineralocorticoid, with considerable glucocorticoid activity in vitro and in vivo (24) . The results of its administration to adrenalectomized rats are shown in Fig. 4 . In terms of plasma and AP levels of ir-ACTH and ir-,BEP, 9afF appears to be -10% as potent as DM, a finding consistent with its 10% thymolytic activity vis-a-vis DM. Like DM, 9affF has no effect on hypothalamic levels of ir-ACTH and ir-4EP; in contrast with DM, however, the higher doses of 9afF are followed by a significant elevation in N-IL content of ir-j3EP (Fig. 4, bottom panel) .
Levels of ir-ACTH and ir-f3EP. Effects of DOC.
DOC is a potent mineralocorticoid, with little or no agonist glucocorticoid activity in most test systems (24) . The doses of DOC used in this study (up to 2, 000 ,gg/d) produced no change in thymus weight, and no significant changes in plasma or AP levels of ir-ACTH and ir-I3EP, comparing individual doses with control groups (Fig. 5, upper panels) . Whether or not the apparent trend at high doses (suppression of plasma levels, increasing AP levels) represents minor partial agonist glucocorticoid activity, as has been shown for some glucocorticoid-inducible enzymes, cannot be answered with the range of doses used.
Like DM and 9afF, DOC administration had no effect on hypothalamic levels of either peptide. Unlike DM-and consistent with the difference between DM and 9afF-DOC administration elevates N-IL content of ir-f3EP; as for 9afF, the levels at >60 ,ug of steroid are significantly elevated (approximately twofold) over control (Fig. 5, lower panels) . 
DISCUSSION
The above findings appear worthy of discussion under several headings. First, anterior pituitary levels of ir-,BEP and ir-ACTH double over a 6-d period after adrenalectomy; those in plasma are raised four-to sixfold after 6 d. These findings suggest that the rates of both precursor synthesis and release of ir-ACTH and ir-f,EP from the anterior pituitary are increased, in response to the removal of glucocorticoid negative feedback inhibition, either directly or via enhanced CRF secretion. A corollary of the increase in both plasma levels and tissue content is that the increase in rate of synGlucocorticoids, Mineralocorticoids, ACTH, and f3-Endorphin thesis is at least marginally greater than the increase in rate of secretion, on the presumption that peripheral clearance is unchanged.
Such increases in plasma and AP content of ir-ACTH and ir-f3EP postadrenalectomy are in general agreement with previous studies (13, 22, 25) ; exact comparisons of the magnitude of the changes are difficult in the light of differences in animal species, sex, age, and length of time postadrenalectomy. In contrast, although both reduced (12) and elevated (13) (26) . Second, we have found that the contents of ir-3EP and ir-ACTH in the AP remain in a close stoichiometric relationship during various experimental manipulations, and that a similar relationship is also found in the plasma throughout the studies. The present findings are consistent with in vitro studies on AP showing that ir-ACTH and ir-f3EP are derived from a common precursor, from which the two peptides are processed in a parallel manner; and that their concurrent release is modulated by both CRF and glucocorticoids (7, 8, 11, 13) . The results, in addition, confirm previous studies (13) (1, 27) , and indirect effects by altering CRF levels (28) . Secondly, the feedback effects of glucocorticoids on ACTH are similarly not simple in terms of time (1, 28, 29) . The present studies were at a single time point after adrenalectomy; AP levels of ir-4EP continue to rise for at least 32 d after adrenalectomy, and-in limited dose studies-continue to be further enhanced by DM 2 gg.2 Our rats were killed 4-6 h after their last injection of steroid in oil. If AP levels are influenced by both fast and slow feedback, the sum of these two processes may be both time and dose dependent. Slow feedback would then show a dose-response curve similar to that for thymolysis; fast feedback would appear shifted to the right, in that only at higher doses of DM or the highest doses of 9afF would there be adequate levels of circulating steroid immediately before killing.
A point that appears worthy of brief discussion is the content and relationship of ir-3EP and ir-ACTH in the hypothalamus. Unlike AP, ir-f3EP content in HT is double that of ir-ACTH; both remain unchanged after both glucocorticoid and mineralocorticoid treat-ment. Recent immunohistochemical studies have shown that ir-aMSH coexists with ir-ACTH in hypothalamic neurons (30) . Moreover, it has also been shown that a large proportion of ir-ACTH is processed into aMSH during axonal transport in HT cells (31) . Since aMSH shows minimal cross-reactivity in our ACTH RIA, our findings of lower levels of ir-ACTH than ir-flEP are consistent with such processing; in addition, the maintained -1:2 ratio after adrenalectomy and during steroid treatment suggests that such processing is affected neither by glucocorticoids nor mineralocorticoids.
The other major finding of the study is that N-IL content of ir-,BEP in adrenalectomized rats is elevated by mineralocorticoid, but not glucocorticoid administration. The changes are smaller in magnitude than the effect of DM on AP; they are induced with equivalent doses of 9afF and DOC. The mechanisms whereby mineralocorticoids elevate N-IL ir-#3EP is currently an area for speculation. High affinity, mineralocorticoid-specific aldosterone binding sites have recently been identified in rat anterior pituitary (15) and pituitary cell lines (16); we have consistently been unable to demonstrate such sites in rat N-IL preparations (Krozowski and Funder, unpublished data). lf there are no mineralocorticoid receptors present in the N-IL, the effect of mineralocorticoids is presumably indirect, and perhaps most plausibly via altered neural input from the hypothalamic dopaminergic system. This would be consistent with in vitro studies, in which it has been shown that the release of N-IL ir-pEP is modulated by dopamine, but is unaffected by corticosteroids (26) .
